Navigation Links
Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
Date:4/23/2012

WASHINGTON, April 23, 2012 /PRNewswire/ --  Covington & Burling represented AstraZeneca in its $1.26 billion acquisition of Ardea Biosciences.  Under the agreement, AstraZeneca will pay $32 per share for all of the outstanding shares of Ardea. 

(Logo: http://photos.prnewswire.com/prnh/20120423/CL92331LOGO )

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. Ardea is a biotechnology company based in San Diego, California, focused on the development of small-molecule therapeutics for the treatment of serious diseases. 

The Covington team was led by Catherine Dargan, with assistance from Stephen Infante and Michael Riella. The team also included John Hurvitz, Emily Leonard, Ashley Nelson, Darien Capron, Brianna Sandoval, Christina Chung, Larry Bartenev and Caitlin Cottingham (life sciences/corporate), Robert Heller and Sarah Burnham (tax), Michael Francese and Katherine Mineka (benefits), Marialuisa Gallozzi and Scott Levitt (insurance), Andrea Reister and Marie Lavalleye (intellectual property), Michael Labson (regulatory), and Deborah Garza, James Dean and Jonathan Herczeg (antitrust). 

Covington & Burling LLP, an international law firm, provides corporate, litigation, and regulatory expertise to enable clients to achieve their goals.  Founded in 1919, the firm has more than 800 lawyers and offices in Beijing, Brussels, London, New York, San Diego, San Francisco, Silicon Valley, and Washington, DC.

Contact

Rebecca Carr


202.662.5110


rcarr@cov.com


'/>"/>
SOURCE Covington & Burling
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. nanoTox COO Greg King Advises Nanotech Companies to View Safety Concerns as an Opportunity to Gain Consumer Trust
2. KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
3. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
4. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
5. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
6. AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer
7. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
8. Rigel Earns Milestone Payments From AstraZeneca
9. TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis
10. AstraZeneca Outlines Principles for Product-Related Online Communications
11. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs ... to include an array of biochemical analyses critical for Lead Discovery. The ... hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, and ...
(Date:2/23/2017)... ATLANTA , Feb. 23, 2017  In Atlanta, it ... art, fashion, and culture intertwine to create an expressive and ... often reflect this energy and contribute to it. ... , Hair Fairies seeks to carry on that ... The Atlanta salon is the newest ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. has ... the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The adjunctive ... during periods of rest. A lightweight, non-invasive monitor is placed on the belly ...
(Date:2/23/2017)... ... , ... Today, researchers can fast-track sample collection and analysis ... biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With the addition ... insulin and other relevant biomarkers can be extensively studied through a non-invasive sample ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/2/2017)... TOKYO , Feb. 1, 2017  Central ... innovative and meaningful advances worldwide, The Japan Prize ... Japan Prize, who have pushed the envelope in ... Information and Communication. Three scientists are being recognized ... outstanding achievements that not only contribute to the ...
Breaking Biology News(10 mins):